A warm welcome to Robert DeBenedetto who has joined Abingworth as Managing Director, CCD. Bob will further enhance Abingworth’s Clinical Co-Development franchise. Welcome to the team, Bob! Find out more: https://lnkd.in/eeczaJF3
About us
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in over 180 life science companies, leading to 46 M&As and 70+ IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022.
- Website
-
http://www.abingworth.com
External link for Abingworth
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- London, UK
- Type
- Privately Held
- Founded
- 1973
- Specialties
- Investing in life sciences
Locations
-
Primary
38 Jermyn Street
London, UK, SW1Y 6DN, GB
-
3000 Sand Hill Road
B4-135
Menlo Park, CA CA 94025, US
-
420 Boylston Street
Suite 405
Boston, MA 02116, US
Employees at Abingworth
Updates
-
We are delighted to co-lead the Myricx Bio series A financing and look forward to supporting the company as it advances its ADC platform and pipeline. Congratulations!
FUNDING NEWS: We are thrilled to announce our £90m ($114m) series A financing, one of the largest biotech series A in European biotech and the largest in the UK this year. The round was co-led by new investors Novo Holdings and Abingworth. Additional new investors British Patient Capital, Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners. The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. Having been a virtual company since spinning out from Imperial College London and The Francis Crick Institute, we will now move to establish laboratory operations in London’s biotech hub and will be expanding our management and R&D teams. Welcome to our new investors and thank you to everyone that has contributed to the progress of the company so far, not least our founding scientists Ed Tate, Roberto Solari and Andy Bell. Exciting times ahead. Read the full release HERE https://lnkd.in/eSu9mP3c #venturecapital #financing #drugdevelopment #UKbiotech
-
Join Tim Haines, Executive Partner & Managing Director, at the UBS Life Sciences Conference in London today for a panel discussion: Life Sciences Fundraising Landscape. Find out more: https://lnkd.in/dfqAphuM
-
Fantastic news for our portfolio company Soleno Therapeutics, Inc. and most importantly for those impacted by Prader-Willi Syndrome.
We’re pleased to share that the U.S. FDA has granted Breakthrough Therapy Designation to diazoxide choline for the treatment of adults and children ages 4 years and older with genetically confirmed #PraderWilliSyndrome (PWS) who have hyperphagia. Thank you to the DCCR Phase 3 program participants, their families and caregivers - you continue to inspire us every day. #RareDisease #PWSAwarenessMonth Read more: https://lnkd.in/gGDwTS97
-
Fantastic news for Abingworth portfolio company Escient Pharmaceuticals today as Incyte announces they will acquire the company. Congratulations! Read more: https://lnkd.in/eEgWnf5u
-
Tim Haines, Executive Partner & Managing Director, will give a keynote speech 'A Review of the Life Sciences Investment Landscape' at OBN (UK) Ltd's BioTrinity 2024 on Tuesday 23 April at 9:15am BST in London. Find out more: https://lnkd.in/e8DS6A-G
-
We’re delighted to announce that we have entered into a strategic development funding agreement with Teva Pharmaceuticals to provide up to $150m to support Phase 3 pivotal clinical trials for their dual-action asthma inhaler respiratory program for severe asthma relief. As part of this agreement, our portfolio company Launch Therapeutics, a clinical development company, has entered into a clinical collaboration agreement with Teva. Find out more: https://lnkd.in/edcakemu
-
Congratulations to our portfolio company IFM Therapeutics on the acquisition of subsidiary IFM Due by Novartis. Another great outcome for the team!
Today we announced that Novartis has exercised an option to acquire all outstanding capital stock of IFM Due, our subsidiary focused on developing novel STING antagonists to address a variety of serious inflammation-driven diseases. This exciting milestone marks our third major acquisition by a global biopharmaceutical company. Learn more about the deal here:
-
We’re pleased to announce that we have entered into a strategic development financing agreement with Gilead Sciences to provide up to $210m in funding to support select clinical studies for Trodelvy® As part of this agreement, our portfolio company Launch Therapeutics, a clinical development company, has entered into a clinical collaboration agreement with Gilead. Find out more: https://lnkd.in/ePrUJ8iv
-
Abingworth reposted this
Today Q32 Bio and Homology Medicines, Inc. announced they have entered into a definitive merger agreement to combine the companies. The Nasdaq-listed company will operate as Q32 Bio and will focus on advancing its wholly owned clinical development candidates for the treatment of #autoimmune and #inflammatorydiseases. Read the press release: https://prn.to/3su6lLA